Literature DB >> 21063505

Yin and Yang Part Deux: CCN5 inhibits the pro-fibrotic effects of CCN2.

Andrew Leask.   

Abstract

There is no treatment for fibrotic disease is a significant cause of mortality. CCN2 Members of the CCN family of matricellular proteins have a characteristic four domain structure. CCN2 (connective tissue growth factor) is believed to play an essential role in fibrogenesis. In a recent paper, data are provided that CCN5 (wisp2), which lacks the carboxy-terminal heparin-binding domain shared by the other CCN proteins, may act as a dominant-negative protein to suppress CCN2-mediated fibrogenesis. These data are consistent with the notion that different CCN proteins may enhance or suppress each other's action and also suggest that CCN5, may be used as a novel anti-fibrotic therapy.

Entities:  

Keywords:  CCN2; CTGF; Fibrosis; wisp2

Year:  2010        PMID: 21063505      PMCID: PMC2948118          DOI: 10.1007/s12079-010-0092-0

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  18 in total

Review 1.  NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues.

Authors:  B Perbal
Journal:  Mol Pathol       Date:  2001-04

2.  Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen.

Authors:  Markella Ponticos; Alan M Holmes; Xu Shi-wen; Patricia Leoni; Korsa Khan; Vineeth S Rajkumar; Rachel K Hoyles; George Bou-Gharios; Carol M Black; Christopher P Denton; David J Abraham; Andrew Leask; Gisela E Lindahl
Journal:  Arthritis Rheum       Date:  2009-07

Review 3.  Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts.

Authors:  G R Grotendorst
Journal:  Cytokine Growth Factor Rev       Date:  1997-09       Impact factor: 7.638

4.  The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis.

Authors:  Pyoung Oh Yoon; Min-Ah Lee; Hyeseon Cha; Moon Hee Jeong; Jooyeon Kim; Seung Pil Jang; Bo Youn Choi; Dongtak Jeong; Dong Kwon Yang; Roger J Hajjar; Woo Jin Park
Journal:  J Mol Cell Cardiol       Date:  2010-04-27       Impact factor: 5.000

5.  N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma.

Authors:  M Dziadzio; W Usinger; A Leask; D Abraham; C M Black; C Denton; R Stratton
Journal:  QJM       Date:  2005-06-13

6.  CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease.

Authors:  Bruce L Riser; Feridoon Najmabadi; Bernard Perbal; Darryl R Peterson; Jo Ann Rambow; Melisa L Riser; Ernest Sukowski; Herman Yeger; Sarah C Riser
Journal:  Am J Pathol       Date:  2009-04-09       Impact factor: 4.307

Review 7.  CCN proteins: multifunctional signalling regulators.

Authors:  Bernard Perbal
Journal:  Lancet       Date:  2004-01-03       Impact factor: 79.321

8.  CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts.

Authors:  Xu Shi-wen; Lee Anne Stanton; Laura Kennedy; Daphne Pala; Yunliang Chen; Sarah L Howat; Elisabetta A Renzoni; David E Carter; George Bou-Gharios; Richard J Stratton; Jeremy D Pearson; Frank Beier; Karen M Lyons; Carol M Black; David J Abraham; Andrew Leask
Journal:  J Biol Chem       Date:  2006-02-16       Impact factor: 5.157

9.  Cooperative regulation of chondrocyte differentiation by CCN2 and CCN3 shown by a comprehensive analysis of the CCN family proteins in cartilage.

Authors:  Harumi Kawaki; Satoshi Kubota; Akiko Suzuki; Noureddine Lazar; Tomohiro Yamada; Tatsushi Matsumura; Toshihiro Ohgawara; Takeyasu Maeda; Bernard Perbal; Karen M Lyons; Masaharu Takigawa
Journal:  J Bone Miner Res       Date:  2008-11       Impact factor: 6.741

10.  Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?

Authors:  Andrew Leask; Sunil K Parapuram; Xu Shi-Wen; D J Abraham
Journal:  J Cell Commun Signal       Date:  2009-01-21       Impact factor: 5.782

View more
  7 in total

1.  Spatial-temporal modulation of CCN proteins during wound healing in human skin in vivo.

Authors:  Laure Rittié; Bernard Perbal; John J Castellot; Jeffrey S Orringer; John J Voorhees; Gary J Fisher
Journal:  J Cell Commun Signal       Date:  2011-01-11       Impact factor: 5.782

2.  CCN2: a bona fide target for anti-fibrotic drug intervention.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2011-03-06       Impact factor: 5.782

3.  CCN6 (WISP3): a new anti-cancer therapy?

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2010-11-09       Impact factor: 5.782

4.  Human pancreatic cancer progression: an anarchy among CCN-siblings.

Authors:  Sushanta K Banerjee; Gargi Maity; Inamul Haque; Arnab Ghosh; Sandipto Sarkar; Vijayalaxmi Gupta; Donald R Campbell; Daniel Von Hoff; Snigdha Banerjee
Journal:  J Cell Commun Signal       Date:  2016-08-19       Impact factor: 5.782

5.  CCN5 attenuates profibrotic phenotypes of fibroblasts through the Smad6-CCN2 pathway: Potential role in epidural fibrosis.

Authors:  Honghai Xu; Cong Liu; Zhengming Sun; Xiong Guo; Yuelin Zhang; Mengting Liu; Peng Li
Journal:  Int J Mol Med       Date:  2015-04-21       Impact factor: 4.101

6.  The matricellular protein CCN5 induces apoptosis in myofibroblasts through SMAD7-mediated inhibition of NFκB.

Authors:  Mai Tuyet Nguyen; Min-Ah Lee; Young-Kook Kim; Hyun Kook; Dongtak Jeong; Seung Pil Jang; Tae Hwan Kwak; Woo Jin Park
Journal:  PLoS One       Date:  2022-08-02       Impact factor: 3.752

Review 7.  Cellular communication network factor 3 in cartilage development and maintenance.

Authors:  Satoshi Kubota; Harumi Kawaki; Bernard Perbal; Kazumi Kawata; Takako Hattori; Takashi Nishida
Journal:  J Cell Commun Signal       Date:  2021-06-14       Impact factor: 5.782

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.